Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
Bioengineer
JANUARY 16, 2024
In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. months vs. 15.2
Let's personalize your content